AlzeCure Pharma Investor Relations Material
Latest events
Study Update
AlzeCure Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AlzeCure Pharma
Access all reports
AlzeCure Pharma AB is a Swedish pharmaceutical company focused on developing treatments for severe diseases related to the central nervous system, particularly Alzheimer's disease. The company operates primarily through two research platforms: NeuroRestore, aimed at restoring cognitive functions by stimulating essential brain signaling pathways, and Alzstatin, which targets reducing the production of amyloid beta, a key factor in Alzheimer's pathology. AlzeCure's drug pipeline includes ACD856, a candidate for treating Alzheimer's, depression, and traumatic brain injuries, currently in phase I clinical trials, as well as several other preclinical candidates for pain and neurodegenerative conditions. AlzeCure is headquartered in Stockholn, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ALZCUR
Country
🇸🇪 Sweden